| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7.0M | +118.8% | -15.5% |
| SG&A Expense | $3.0M | -24.3% | -12.7% |
| Operating Income | -$10.0M | -39.1% | +28.4% |
| Net Income | -$9.4M | -44.7% | +26.6% |
| EPS (Basic) | -$0.31 | -47.6% | +27.9% |
| EPS (Diluted) | -$0.31 | -47.6% | +27.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $18.0M | -1.2% | -46.3% |
| Current Assets | $64.0M | -5.2% | -34.5% |
| Total Assets | $67.2M | -11.3% | -31.2% |
| Total Liabilities | $6.9M | -1.8% | -31.5% |
| Stockholders' Equity | $60.4M | -12.3% | -31.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$24.6M | — | — |
| Investing Cash Flow | $21.1M | — | — |
| Financing Cash Flow | $113K | — | — |